How does the USPTO handle enablement issues in drug-related patent applications?
For drug-related patent applications, the USPTO has specific guidelines addressing enablement issues. The MPEP 2164.06(a) directs examiners and applicants to additional resources: See MPEP § 2107 – § 2107.03 for a discussion of the utility requirement under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, in drug cases. This reference to MPEP §…
Read More